Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study *

By D. Dempster, F. Cosman, E. Kurland, Hua Zhou, J. Nieves, L. Woelfert, E. Shane, Katarina Plavetić, R. Müller, J. Bilezikian and 1 more. Journal of Bone and Mineral Research, 2001

647 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/f89f64120800abb29ce1ea03bce66691caff421e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. E. Eriksen
2. M. McClung

In Oncology

1. E. Eriksen
2. M. McClung

In Orthopedics and Sports Medicine

1. E. Eriksen
2. M. McClung

Citations in the corpus

• Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. (2005, background): “Such improvements in cortical bone architecture with teriparatide treatment are now beginning to be documented in humans using a variety of techniques, including histomorphometry (40, 46), peripheral quantitative computed tomography (QCT) (58–61), radiogrammetry (62), and absorptiometric assessment ”
• Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure (2003, background): “Three studies((13,14,17)) found that PTH peptides significantly increase cancellous bone volume, and the other two studies found significant increases in cortical thickness by twodimensional (2D)((15)) and three-dimensional (3D)((16)) analyses.”